The nasal vaccine against COVID-19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
iNCOVACC is a novel adenovirus vectored, intranasal vaccine for COVID-19. It has various advantages over injectable vaccines. Here are a few of them.

The two-drop nasal vaccine, iNCOVACC is manufactured by Bharat Biotech, India. It is a novel adenovirus vectored, intranasal vaccine for COVID-19 that can stimulate a broad immune response – neutralizing IgG, mucosal IgA, and T cell responses. 

How does it work?

The nasal vaccine is delivered through the nose or mouth. It is expected to work on the mucosal lining. Thus, the nasal vaccine prompts an immune response at the entry points of the virus which is mostly the nose and the mouth. This prevents infection at the entry point itself thereby protecting against disease, infection, and transmission. It is referred to as sterilizing immunity. Many studies have found that nasal delivery of vaccines is capable of creating a strong immune response.

Mice, Hamsters and macaques were immunized with a single dose of ChAd-SARS-CoV-2-S conferred superior protection against the SARS-CoV-2 challenge. Post-challenge with SARS-CoV-2, viral clearance was observed in both lower and upper airways in all these animal models.

Nasal vaccines v/s Injectable vaccines

Nasal vaccines have a proven benefit over injectable vaccines. In the third phase of the clinical trial which was done on 3,000 participants, iNCOVACC showed good immunity with 2 doses given 4 weeks apart.

Advantages of the nasal vaccine

  • An immune response at the site of infection is essential for blocking both infection and transmission of COVID-19.
  • Non-invasive, Needle-free
  • Ease of administration – does not require trained healthcare workers
  • Elimination of needle-associated risks (injuries and infections)
  • High compliance

Nasal vaccine composition

0.5 ml of this nasal vaccine contains NLT 5X10 particles per mL ChAd36-SARS-CoV-S COVID-19 virus (recombinant) including excipients such as Tris (pH 7.4), Sodium Chloride, Magnesium Chloride, Glycerol, Polysorbate- 80.

Those who have taken Covishield and Covaxin can take the nasal vaccine as a heterologous booster dose. In heterologous boosting, a person administered a different vaccine from the one that was used for the primary dose series.

The nasal vaccine as a booster dose and not the fourth dose after the booster shot

The nasal vaccine is recommended as a first booster and cannot be administered after one has taken the booster or the precautionary dose. This is because by repeatedly immunizing with a particular type of antigen, the body stops responding or responds poorly. Therefore, taking the nasal vaccine as the fourth dose after taking the booster dose is of no value.

Tags : #COVID19 #Nasalvaccine #Vaccination #VaccineforCOVID19 #iNCOVACC #MadeinIndiavaccine #NasalvaccineforCOVID19 #Medicircle #SmitaKumar

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Top 4 IVF Centres for High Success RatesJune 24, 2025
Former President Ram Nath Kovind to Inaugurate National Conference of CA Students 2025 in KolkataJune 24, 2025
Bollywood actor Salman Khan says he is suffering from a brain aneurysm, what you need to know about the conditionJune 24, 2025
Butterfly Unveils a Bold New Identity That Celebrates Change and Champions the Original YouJune 24, 2025
8 Daily Habits to Keep Arthritis at BayJune 24, 2025
Food Safety and Drug Administration (FDA), Goa, National Association of Street Vendors of India (NASVI) and Nestlé India expand Project ‘Serve Safe Food’ in GoaJune 24, 2025
Top 4 Startups Driving Credit Risk Innovation in India’s Healthcare and Pharma SectorJune 24, 2025
Sova Health to Host a Free Masterclass on World Microbiome Day, Demystifying Digestive HealthJune 24, 2025
Doctor-Approved Hacks for Better Sleep TonightJune 24, 2025
Indian Assistive Technology Pioneer Prateek Madhav Champions Global Disability Tech Reform with The Royal Society of London Report LaunchJune 24, 2025
Wow! Momo Launches India’s First Gluten-Free Range of Momos – A Game-Changer for Health Conscious FoodiesJune 24, 2025
Medicolegal Risks in TelemedicineJune 24, 2025
Digital Mental Health Clinics in Tier-2 CitiesJune 24, 2025
AssisTech Foundation Hosts Inclusive Job Festival for Persons with DisabilitiesJune 23, 2025
Travel with Ease: Why Congestion Patches Are the Smart Traveler’s Secret WeaponJune 23, 2025
Paper-Tech Platform Paper Arizona Hits ₹100 Cr Annual Revenue Milestone, Eyes IPO Listing in 2026June 23, 2025
Eat Better to enhance its Quick Commerce Operations with UnicommerceJune 23, 2025
Stahl Unveils Blacksmith Signature Cast Iron Tawas: A Classic Essential with a Modern Update for Timeless Indian KitchensJune 23, 2025
Lilly’s once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trialsJune 23, 2025
Finding strength in struggle for gender equality and human rightsJune 23, 2025